MYC

[Proceedings of the National Academy of Sciences of the United States of America] Treatment of breast cancer cells with a small-molecule inhibitor of BRD4, JQ1, resulted in no immediate activation of the drug-resistant genes, but long-time treatment or destabilization of LSD1 by PELI1 decommissioned the BRD4/LSD1/NuRD complex.

[Nature Metabolism] In vitro expression of Mycl provoked active replication in islet cells, even in those from aged mice.

[Clinical Cancer Research] Scientists tested if inhibition of DOT1L, an epigenetic regulator of normal tissue stem/progenitor populations, would target triple negative breast cancers stem cells.

[Nature Communications] Scientists showed RIPK2 was a clinically actionable target for inhibiting prostate cancer (PC) metastasis. RIPK2 was amplified/gained in ~65% of lethal metastatic castration-resistant PC.

[Cancer Gene Therapy] Cyclin-dependent kinase 12 (CDK12) activated MYC to repress miR-28-5p/EZH2 and amplified tonic BCR signaling to promote the development of diffuse large B cell lymphoma (DLBCL), which might provide potential therapeutic targets for future therapeutic intervention in DLBCL.

[Cancer Cell] Researchers proposed that lactic acid in the highly glycolytic tumor microenvironment (TME) was an active checkpoint for the function of regulatory T cells in the TME via upregulation of PD-1 expression.